Top Page
CSL
(OTC:CSL)
CSL (CSL) vs. iShares MSCI Australia ETF (EWA)
CSL Business Overview & Revenue Model
CSL Earnings Call Summary
CSL Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.47B | 15.43B | 14.69B | 13.17B | 10.49B | 10.33B |
| Gross Profit | 7.64B | 7.95B | 7.56B | 6.71B | 5.66B | 5.80B |
| EBITDA | 5.23B | 5.13B | 4.73B | 3.90B | 3.46B | 3.63B |
| Net Income | 3.04B | 3.00B | 2.64B | 2.19B | 2.25B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 39.54B | 39.40B | 38.02B | 54.43B | 41.22B | 18.16B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.16B | 1.66B | 2.33B | 15.18B | 1.81B |
| Total Debt | 11.65B | 11.50B | 12.18B | 18.37B | 14.04B | 5.81B |
| Total Liabilities | 18.06B | 18.00B | 18.62B | 27.65B | 20.02B | 9.74B |
| Stockholders Equity | 19.40B | 19.34B | 17.33B | 23.72B | 21.20B | 8.38B |
Cash Flow | ||||||
| Free Cash Flow | 3.04B | 2.54B | 1.51B | 1.35B | 1.90B | 1.97B |
| Operating Cash Flow | 3.70B | 3.56B | 2.81B | 3.87B | 3.62B | 3.65B |
| Investing Cash Flow | -882.99M | -850.00M | -1.26B | -17.61B | -2.26B | -1.68B |
| Financing Cash Flow | -2.33B | -2.24B | -1.28B | 677.92M | 10.58B | -1.41B |
CSL Technical Analysis
CSL Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.50B | 17.20 | 54.79% | ― | 12.35% | 26.73% | |
75 Outperform | AU$88.21B | 18.99 | 16.36% | 2.49% | 6.07% | 13.75% | |
73 Outperform | AU$637.55M | 17.58 | 15.90% | 0.39% | 7.76% | 1.55% | |
65 Neutral | $4.94B | 287.55 | 3.21% | ― | 60.23% | -66.98% | |
55 Neutral | $3.50B | ― | -18.95% | ― | 198.58% | 3.97% | |
52 Neutral | AU$375.80M | ― | -35.86% | ― | ― | -19.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSL Corporate Events
CSL Limited announced the cessation of 32,733 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders, reflecting the company’s ongoing adjustments in managing its securities and market positioning.
CSL Limited has announced an update regarding its ongoing share buy-back program. As of December 5, 2025, the company has repurchased a total of 2,551,319 ordinary fully paid securities, with 41,657 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, which can have implications for the company’s market positioning and investor relations.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 42,359 ordinary fully paid securities. This buy-back initiative, which began on August 20, 2025, is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting the company’s commitment to maintaining a balanced approach to capital management.
CSL Limited has announced the appointment of Gordon Naylor as a director, effective December 1, 2025. This appointment is accompanied by the disclosure of Naylor’s interests in CSL securities, including 39,719 ordinary shares directly held and 54,992 shares held indirectly through Netwealth Investments Limited. This move is significant for CSL as it strengthens its leadership team with Naylor’s expertise, potentially impacting its strategic direction and stakeholder confidence.
CSL Limited announced the issuance and conversion of unquoted equity securities, specifically 11,594 ordinary fully paid shares, effective from December 1, 2025. This move is part of the company’s strategic financial operations, potentially impacting its capital structure and offering insights into its ongoing growth and investment strategies.
CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,341,481 securities have been bought back prior to the latest update, with an additional 46,706 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of November 26, 2025, the company has repurchased a total of 2,341,481 securities, including 38,684 bought back on the previous day. This buy-back initiative reflects CSL’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
CSL Limited announced a change in the director’s interest, with Dr. Brian Daniels acquiring 1,700 American Depositary Receipts (ADRs), representing 3,400 ordinary shares in the company. This on-market purchase reflects an increase in Dr. Daniels’ indirect interest in CSL, potentially signaling confidence in the company’s future performance and stability, which could positively impact stakeholder perception.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it has bought back a total of 2,235,368 ordinary fully paid securities before the previous day and an additional 43,399 securities on the previous day. This buy-back initiative is part of CSL’s efforts to manage its capital structure and potentially enhance shareholder value.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 49,785 ordinary fully paid securities bought back on the previous day, adding to a cumulative total of 2,185,583 securities. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting the company’s robust financial health and commitment to efficient capital management.
CSL Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 2,139,429 ordinary fully paid securities have been bought back to date, with an additional 46,154 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting a positive outlook on the company’s financial health and market positioning.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid securities. As of November 19, 2025, the company has bought back a total of 2,079,952 securities, with an additional 59,477 securities repurchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value.
CSL Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 1,983,576 securities have been bought back prior to the previous day, with an additional 48,811 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting the company’s confidence in its financial health and future prospects.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 1,936,615 ordinary fully paid securities, with an additional 46,961 securities bought back on the previous day. This buy-back initiative reflects CSL’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of November 12, 2025, the company has repurchased a total of 1,846,467 of its ordinary fully paid securities, with an additional 50,512 bought back on the previous day. This buy-back initiative is part of CSL’s strategic efforts to manage its capital structure and enhance shareholder value.
CSL Limited announced the cessation of 50,194 securities due to the lapse of conditional rights, as the conditions were not met or became unachievable. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting the challenges in meeting certain operational conditions.
CSL Limited has announced an update regarding its ongoing on-market buy-back program for its ordinary fully paid securities. As of the latest notification, the company has bought back a total of 1,807,326 securities before the previous day and an additional 39,141 securities on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value.
CSL Limited announced the cessation of 410 securities due to the lapse of conditional rights, as the conditions required for these rights were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital and reflects the company’s ongoing management of its securities and financial operations.
CSL Limited announced the issuance of 200 ordinary fully paid securities, effective November 5, 2025. This move indicates an ongoing strategy to enhance its capital structure, potentially impacting its market positioning and offering implications for stakeholders regarding the company’s financial strategies.
CSL Limited announced its Capital Markets Day event to be held in Chicago, Illinois, USA. The event will provide insights into the company’s strategic direction and operational performance, with recordings available online for those unable to attend due to time zone differences. This event reflects CSL’s commitment to transparency and engagement with its investors, potentially impacting its market positioning and stakeholder relations positively.
CSL Limited announced its upcoming Capital Markets Day event to be held in Chicago, Illinois, USA, which will include a briefing for investors and analysts. The event, aimed at providing insights into the company’s strategic direction and financial performance, will be webcast live on the company’s website, highlighting CSL’s commitment to transparency and stakeholder engagement.
CSL Limited has announced its upcoming Capital Markets Day event, scheduled for November 4-5, 2025, in Chicago, Illinois. The event will feature presentations on the company’s business activities and growth initiatives, with live webcasts available for the initial session and recordings accessible afterward. This event is expected to provide insights into CSL’s strategic direction and operational plans, potentially impacting investor perceptions and market positioning.
CSL Limited announced a change in the interests of Dr. Paul McKenzie, a director of the company, involving the grant of 58,360 Performance Share Units as part of a long-term incentive plan. This change, approved by shareholders at the 2025 Annual General Meeting, is intended to align the director’s interests with the company’s long-term performance goals, potentially impacting CSL’s strategic direction and stakeholder confidence.
CSL Limited announced the issuance of 58,360 unquoted securities under an employee incentive scheme, which are subject to transfer restrictions and not listed on the ASX until these restrictions are lifted. This move is part of CSL’s strategy to incentivize and retain talent, potentially impacting its operational dynamics and stakeholder engagement by aligning employee interests with company performance.
CSL Limited has announced the cessation of Megan Clark as a director, effective October 28, 2025. This change in the board composition is accompanied by details of her interests in the company’s securities, which include 3,883 ordinary fully paid shares held directly and additional shares and rights held indirectly through Solium Nominees (Australia) Pty Ltd. This update is part of CSL’s compliance with regulatory requirements and may influence stakeholders’ perspectives on the company’s governance and strategic direction.
CSL Limited’s 2025 Annual General Meeting, held in Melbourne, revealed key shareholder voting outcomes on several resolutions. Notably, the ‘second strike’ against the Remuneration Report was recorded, triggering a conditional Spill Resolution, which was ultimately not carried. The meeting also saw the election of directors and approval of performance share units, reflecting the company’s ongoing governance and strategic initiatives.
CSL Limited held its 2025 Annual General Meeting in Melbourne, where key updates were provided regarding financial projections for 2026-2028 and a proposal to demerge CSL Seqirus. The meeting underscored the company’s strategic direction amidst current market challenges, emphasizing its commitment to sustainable and profitable growth. The AGM also highlighted changes in board membership, with some directors retiring and others standing for election, reflecting a robust governance structure.
CSL Limited has announced an update regarding its ongoing share buyback program, with UBS Securities Australia Limited replacing JP Morgan as the broker. This change in broker details signifies a strategic adjustment in the execution of CSL’s buyback plan, potentially impacting its market operations and shareholder value.
CSL Limited announced the cessation of 9,078 securities due to the lapse of conditional rights as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders regarding the company’s operational strategies and market positioning.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of October 6, 2025, the company has repurchased a total of 1,729,549 ordinary fully paid securities, with 56,837 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and optimizing the company’s financial performance.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of October 3, 2025, the company has repurchased a total of 1,584,356 ordinary fully paid securities, with an additional 88,356 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, potentially impacting its stock market performance and investor relations.
CSL Limited has announced the appointment of Cameron Bruce Price as a new director, effective from October 1, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, potentially impacting its strategic direction and stakeholder relations. Mr. Price holds no direct shares but has an indirect interest through his wife, who owns 3,296 ordinary shares.
CSL Limited has announced the appointment of Mr. Ken Lim as the new Chief Financial Officer, effective October 7, 2025, succeeding Ms. Joy Linton, who will retire after a transition period. Mr. Lim, previously the Chief Strategy Officer, brings over a decade of experience at CSL, and his appointment reflects the company’s strong executive talent pool. This leadership change is expected to maintain CSL’s strategic direction and continue delivering value to its stakeholders.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 29, 2025, the company has bought back a total of 1,476,163 securities, with an additional 108,193 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategic financial management, potentially impacting its market positioning and shareholder value.
CSL Limited has announced an update regarding its ongoing share buy-back program. As of September 26, 2025, the company has repurchased a total of 1,476,163 ordinary fully paid securities, with 74,423 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting positively on its market positioning.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 24, 2025, the company has bought back a total of 1,311,784 securities, including 62,957 on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning by reducing the number of outstanding shares.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 19, 2025, the company has repurchased a total of 906,265 ordinary fully paid securities, with an additional 130,000 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in its financial health and future growth prospects.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 773,583 securities bought back before the previous day and an additional 132,682 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing the company’s stock performance and market perception.
CSL Limited has announced the details for its 2025 Annual General Meeting, scheduled to take place on October 28, 2025, at the RACV Club in Melbourne. This meeting is a significant event for shareholders, providing an opportunity to discuss the company’s performance and future strategies, potentially impacting its market positioning and stakeholder interests.
CSL Limited has partnered with Dutch biotech firm VarmX to develop VMX-C001, a first-in-class treatment aimed at restoring blood coagulation in patients on FXa inhibitors who experience severe bleeding or require urgent surgery. This collaboration aligns with CSL’s strategy to expand its clinical and commercial pipeline through external partnerships. The U.S. FDA has granted Fast Track Designation to VMX-C001, highlighting its potential to meet a critical unmet medical need. CSL will fund the global Phase 3 trial and has secured an exclusive option to acquire VarmX, with commercial launch anticipated in 2029.
CSL Limited has announced an update on its ongoing on-market buy-back program. As of September 15, 2025, the company has repurchased a total of 773,583 ordinary fully paid securities, with 47,865 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value.
CSL Limited has updated its previous dividend announcement to include details on currency rates and local currency conversions. This update pertains to the dividend distribution for the six-month period ending June 30, 2025, with a record date of September 10, 2025. The announcement reflects the company’s ongoing commitment to transparency and provides stakeholders with crucial financial information.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 12, 2025, the company has repurchased a total of 725,718 ordinary fully paid securities, with 135,502 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and enhance shareholder value.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 11, 2025, the company has repurchased a total of 590,216 ordinary fully paid securities, with 64,826 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders.
CSL Limited has announced the issuance of 1,592,335 unquoted securities under an employee incentive scheme. These securities are subject to transfer restrictions and will not be quoted on the ASX until the restrictions are lifted. This move is part of CSL’s strategy to incentivize and retain talent, which is crucial for maintaining its competitive edge in the biotechnology sector.
CSL Limited announced the issuance of 150,485 ordinary fully paid securities under an employee incentive scheme, which are set to be quoted on the Australian Securities Exchange. This move is part of CSL’s efforts to incentivize its workforce and align employee interests with company performance, potentially impacting its market positioning and stakeholder engagement positively.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 10, 2025, the company has repurchased a total of 396,615 ordinary fully paid securities, with 128,775 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and potentially enhance shareholder value.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 9, 2025, the company reported buying back a total of 292,931 securities before the previous day and an additional 103,684 securities on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure efficiently, potentially enhancing shareholder value by reducing the number of outstanding shares.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back 143,219 ordinary fully paid securities on the previous day, adding to a total of 149,712 securities bought back before that day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, which may impact its stock liquidity and share price.